I am a 5th year PhD student in the lab of Bart De Strooper at VIB-KULeuven Center for Brain & Disease Research.

I am an Assistant Professor of Pathology at UT Health San Antonio, a board-certified neuropathologist, Co-Director of the Biggs Institute Brain Bank and Neuropathology Core Leader at the South Texas Alzheimer Disease Research Center (ADRC). My research has focused on PART, as well as resistance and resilience to AD. We are using spatial metabolomics in this study, comparing AD to gliomas, knowing that their occurrence appears to be diametrically opposed. We are interested in understanding this inverse relationship in order to identify protective pathways for either disease.

Dr. Lauren Walker is an Alzheimer's Research UK fellow at the Translational and Clinical Research Institute at Newcastle University. Her research focusses on neurodegenerative diseases that affect the ageing brain, with a particular interest on the impact of multiple pathologies in the clinical and pathological phenotypes of Lewy body diseases. Her studies have mainly focussed on histological evaluation of human post-mortem tissue and uses high-throughput automated quantitative neuropathological assessment from extensively clinically characterised cases, with the aim of teasing out distinct subtypes of neurodegenerative diseases. Current research aims are to incorporate in vivo studies to investigate when the onset of pathology may have an impact on the clinical and neuropathological outcomes of mixed dementia.

Dr. Dominic Walsh joined Biogen in September 2018 as head of the Alzheimer’s Disease & Dementia Research Unit and in March 2020 became head of the newly founded Neurodegenerative Diseases Research Unit (NDRU). Until recently he also served as the interim head of the Neuromuscular Research Unit. Dominic is responsible for overseeing Biogen’s research on Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. He has worked on the molecular pathology of neurodegeneration since December 1991; has authored over 150 research articles, written several widely cited reviews and given over 100 invited lectures and webinars. He has served as an Editor or Editorial Advisor for several journals and as an ad hoc reviewer for all the world’s leading biomedical journals. Dominic has also served as a consultant and/or SAB member for several pharmaceutical and biotechnology companies. Prior to joining Biogen his research was supported by multiple agencies, grants from industry and donations from the public. He was named one of The World’s Most Influential Scientific Minds by Thomson Reuters and ranked among the top 1% of researchers in the field of Neuroscience and Behavior 2014 - 2016. Currently, Dominic is a SAB member of the Dementia Discovery Fund and of the UK Dementia Research Institute at Imperial College London. He is also an Honorary Professor at the Institute of Neurology, University College London.

Dr. Walters is a Research Associate Professor in the Department of Medicinal Chemistry at the University of Minnesota (UMN). He is one of the core directors in the Institute for Therapeutics Discovery and Development at the UMN and is an expert in medicinal chemistry, computational chemistry, and cheminformatics.

Dr. Wang is a senior scientist with more than 10 years of extensive experience in analyses of human genetic data, quality control of phenotype and genetic data, and bioinformatics annotation of research projects. She obtained her PhD in Medical Science from Chinese Academy of Medical Sciences in Peking, China in 2000 and joined Washington University in 2000 as a medical scientist. In 2011, she obtained MS in Genetic Epidemiology from Washington University and worked as a research statistician in Division of Statistics Genomics before joining Cruchaga’s lab. She has participated in many NIH-funded grants related to the blood pressure, lipids, diabetes, blood cells, kidney function, and cardiometabolic traits. She has involved in multi-ethinic meta-analyses using 1000 genomes imputation and HRC imputation data, rare variants analyses in candidate gene resequencing family data, causal variants identification for aging related traits using linkage and association analyses from WGS data, and alignment, variant calling and QC of WGS data.

Tina is a PhD candidate at McGill Centre for Studies in Aging. She obtained her MSc degree from Imperial College London. Her thesis involved utilising MRI and FDG-PET to study the influence of anti-diabetic drug on neurodegeneration in Alzheimer's disease patients (ELAD study). Currently her research focuses on using multimodal imaging techniques (mainly PET) and fluid biomarkers to identify and study the earliest phases of Alzheimer's disease. She is also investigating the impact of genetics on AD aetiology and progression.

Education 2009.4-2013.3 Bachelor Degree in Dept. of Life science and Medical Bioscience, School of Advanced Science and engineering, University of Waseda in Japan 2013.4-2015.3 Master’s Degree in Department of Life science and Medical Bioscience, Graduate School of Advanced Science and engineering, Waseda University in Japan 2015.4-2018.3 Doctor’s Degree in Department of Life science and Medical Bioscience, Graduate School of Advanced Science and engineering, Waseda University in Japan (PhD of Science) Academic appointment 2015.4-2018.3 Junior Research Associate in Laboratory for Proteolytic Neuroscience RIKEN Center for Brain Science. 2018.4- Pos-doc in Laboratory for Proteolytic Neuroscience RIKEN Center for Brain Science. 2018.4- Part-time teacher at Teikyo University of Science

Carina Wattmo began work in the medical field as a Registered Nurse. Her broad background includes Bachelor of Science degrees in Business Administration and Statistics, and many years of work experience as a controller and medical statistician at the Psychogeriatric Clinic, Lund University Hospital, Lund and at the Neuropsychiatric Clinic, Malmö University Hospital, Malmö, Sweden. Wattmo became more interested in medical research and she obtained a PhD from Lund University in Medical Science, focusing on Alzheimer’s disease (AD) progression and the development of prediction models to estimate the cognitive and functional longitudinal outcomes in cholinesterase inhibitor-treated patients. She currently works as a researcher and is affiliated at the Clinical Memory Research Unit, Lund University. Wattmo continues to expand the dimensions of her research by investigating potential risk factors that affect various aspects of disease progression and endpoints in different subgroups of patients with AD, as well as developing empirical statistical models that may be useful in studies of future therapies. She attends several international conferences annually and gives oral communications and poster presentations. Wattmo also delivers lectures to physicians and health-care professionals working in the field of dementia, and to local politicians, the general public, and Rotary Club members, among others.